Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482354 | 1.00 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2BCHE | |
| Indole SCHEMBL26133665 | 0.83 | AHR (0.49) | MAPTGAA | |
| SCHEMBL30823596 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL30462264 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29181630 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL31188758 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL9935617 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29605097 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL460837 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL7414784 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108324718-B | Application of cyclohexyl methoxy formyl amino chloro benzo aza group quinazoline compound in leukemia treatment drug | 浙江工业大学 | 2020-10-09 | — | — | CN | disclosed |
| US-6861420-B2 | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1451176-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003045940-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | MAPT 2592/4885GAA 618/4885RAB9A 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.